These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 36619796)

  • 1. Performance of Restricted Mean Survival Time Based Methods and Traditional Survival Methods: An Application in an Oncological Data.
    Huang Q; Tian C
    Comput Math Methods Med; 2022; 2022():7264382. PubMed ID: 36619796
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Restricted mean survival time regression model with time-dependent covariates.
    Zhang C; Huang B; Wu H; Yuan H; Hou Y; Chen Z
    Stat Med; 2022 Sep; 41(21):4081-4090. PubMed ID: 35746886
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
    Latimer NR; Abrams KR; Siebert U
    BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Dynamic RMST curves for survival analysis in clinical trials.
    Liao JJZ; Liu GF; Wu WC
    BMC Med Res Methodol; 2020 Aug; 20(1):218. PubMed ID: 32854619
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of the restricted mean survival time with the hazard ratio in superiority trials with a time-to-event end point.
    Huang B; Kuan PF
    Pharm Stat; 2018 May; 17(3):202-213. PubMed ID: 29282880
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Doubly robust estimator of risk in the presence of censoring dependent on time-varying covariates: application to a primary prevention trial for coronary events with pravastatin.
    Kawahara T; Shinozaki T; Matsuyama Y
    BMC Med Res Methodol; 2020 Jul; 20(1):204. PubMed ID: 32736528
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Application of restricted mean survival time in clinical follow-up study].
    Yang ZJ; Lyu JJ; Hou YW; Chen Z
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Feb; 40(2):247-250. PubMed ID: 30744281
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Regression modeling of restricted mean survival time for left-truncated right-censored data.
    Rong R; Ning J; Zhu H
    Stat Med; 2022 Jul; 41(16):3003-3021. PubMed ID: 35708238
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjusting for covariates in analysis based on restricted mean survival times.
    Zhong Y; Zhao O; Zhang B; Yao B
    Pharm Stat; 2022 Jan; 21(1):38-54. PubMed ID: 34231308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of baseline covariate adjustment methods for restricted mean survival time.
    Hanada K; Moriya J; Kojima M
    Contemp Clin Trials; 2024 Mar; 138():107440. PubMed ID: 38228232
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Assessing surrogacy using restricted mean survival time ratio for overall survival in non-small cell lung cancer immunotherapy studies.
    Pang H; Yang G; Ho JC; Leung TH; Shi Q; Hu C; Stinchcombe TE; Wang X
    Chin Clin Oncol; 2022 Feb; 11(1):7. PubMed ID: 35255696
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restricted mean survival time as a summary measure of time-to-event outcome.
    Hasegawa T; Misawa S; Nakagawa S; Tanaka S; Tanase T; Ugai H; Wakana A; Yodo Y; Tsuchiya S; Suganami H;
    Pharm Stat; 2020 Jul; 19(4):436-453. PubMed ID: 32072769
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Semiparametric Additive Modeling of the Restricted Mean Survival Time.
    Zhang Y; Schaubel DE
    Biom J; 2024 Sep; 66(6):e202200371. PubMed ID: 39149839
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Use of the Restricted Mean Survival Time as a Treatment Measure in HIV/AIDS Clinical Trial: Reanalysis of the ACTG A5257 Trial.
    Abulizi X; Ribaudo HJ; Flandre P
    J Acquir Immune Defic Syndr; 2019 May; 81(1):44-51. PubMed ID: 30789450
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ratio and difference of average hazard with survival weight: New measures to quantify survival benefit of new therapy.
    Uno H; Horiguchi M
    Stat Med; 2023 Mar; 42(7):936-952. PubMed ID: 36604833
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Interpretability of Cancer Clinical Trial Results Using Restricted Mean Survival Time as an Alternative to the Hazard Ratio.
    Pak K; Uno H; Kim DH; Tian L; Kane RC; Takeuchi M; Fu H; Claggett B; Wei LJ
    JAMA Oncol; 2017 Dec; 3(12):1692-1696. PubMed ID: 28975263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of Treatment Effects Measured by the Hazard Ratio and by the Ratio of Restricted Mean Survival Times in Oncology Randomized Controlled Trials.
    Trinquart L; Jacot J; Conner SC; Porcher R
    J Clin Oncol; 2016 May; 34(15):1813-9. PubMed ID: 26884584
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiply robust causal inference of the restricted mean survival time difference.
    Shu D; Mukhopadhyay S; Uno H; Gerber JS; Schaubel DE
    Stat Methods Med Res; 2023 Dec; 32(12):2386-2404. PubMed ID: 37965684
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of dynamic restricted mean survival time based on pseudo-observations.
    Yang Z; Zhang C; Hou Y; Chen Z
    Biometrics; 2023 Dec; 79(4):3690-3700. PubMed ID: 37337620
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quantifying treatment differences in confirmatory trials under non-proportional hazards.
    Jiménez JL
    J Appl Stat; 2022; 49(2):466-484. PubMed ID: 35707213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.